Aram Lyu retweeted
Meet 2023 Parker Scholar Aram Lyu, PhD @aramlyu @UCSFMedicine. He is using myeloid cells to mediate immunotherapy resistance in prostate cancer that has metastasized. Hear his thoughts on the future of #cancerresearch here: youtube.com/shorts/GwanyfFn8…
#PICINetwork
Aram Lyu retweeted
Today we announced our 2023 class of Early Career Researcher awardees – 8 exceptional graduate and postdoctoral researchers from leading academic institutions who will share up to $2.9 million for their innovative research #PICINetwork
Meet them here: youtu.be/MGxLtPYNaMs
Aram Lyu retweeted
Celebrating the next generation of researchers at the @AACR Annual Meeting! @AndreaMiyahira joined the 2026 recipients of the PCF Scholar-in-Training Awards, recognizing outstanding early-career scientists presenting impactful work in prostate cancer. #AACR26
Aram Lyu retweeted
Welcome to the 2026 #SITC #Sparkathon participants (Sparkies). We would like to thank them for participating in this unique program to advance their careers in immuno-oncology! #TCells #IO #SITCQuestfor100
Aram Lyu retweeted
The 2024 Young Investigator Awards recipients have just been announced. Congrats to this year’s class, who received $6.3 million in funding for innovative prostate cancer research.
Meet this year’s class: bit.ly/YIAwardsClass2024
#ProstateCancer #MedEd #MedX
Aram Lyu retweeted
Aram Lyu, Peiqi Ou, Helen Rizos, and Annette Paschen discuss "Cancer Immune Evasion" in a symposium at the AACR IO Conference on Discovery and Innovation in Cancer Immunology. #AACRIO25 @HelenRizos @AramLyu
Aram Lyu retweeted
Nature research paper: Evolution of myeloid-mediated immunotherapy resistance in prostate cancer go.nature.com/4f2rSNq
Aram Lyu retweeted
ScRNAseq of prostate cancer samples revealed an SPP1hi TAM population that correlated with progression and T cell exhaustion. bit.ly/3ZPj4Fk @AramLyu @parkerici @lawfong
Aram Lyu retweeted
Fred Hutch researchers shared new research at the @sitcancer meeting in early Nov. Findings included new strategies to avoid T-cell exhaustion in CAR T cells & insights into how solid tumors change microenvironment to blunt the immune system’s response.
bit.ly/4gbmvwI
Aram Lyu retweeted
Why has immunotherapy, transformative for some cancers, struggled in prostate cancer? A new @Nature study, led by @lawfong (former PICI Co-Director at @UCSF, now at @fredhutch) with 1st author Aram Lyu, PhD (PICI Investigator, UCSF), uncovers key insights. 1/3
Aram Lyu retweeted
We are happy to share our work led by @AramLyu and Zenghua Fan on why prostate cancer is so resistant to immunotherapy.
nature.com/articles/s41586-0…

















